Irbesartan and Atenolol in Hypertensive Heart Disease (SILVHIA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00389168|
Recruitment Status : Completed
First Posted : October 18, 2006
Results First Posted : May 5, 2015
Last Update Posted : May 5, 2015
|Study Design||Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment|
|Recruitment Details||Multicenter Swedish study. Patients with primary hypertension and left ventricular (LV) hypertrophy.|
All participants received a placebo washout period during 4 weeks at the beginning of the study.
One patient of the 115 included was during the course of the study diagnosed with Mb Conn (adrenal tumor causing endocrine secondary hypertension). This patient was excluded from all analyses. Thus, there are 114 patients included in the dataset.